Hemophilia

Data for Advate confirm safety and efficacy in hemophilia A patients

Published in Drug Week, September 9th, 2005

Baxter Healthcare Corp. announced the presentation of data from two company-sponsored clinical studies at the 20th Congress of the International Society on Thrombosis and Haemostasis held in Sydney, Australia.

The results provide further evidence for the safety, immunogenicity, and efficacy of Advate in the treatment of individuals with hemophilia A.

"We are committed to expanding our data on Advate with extensive follow-up clinical investigations and analyses of this product in a variety of medical settings," said Bruce Ewenstein, MD, PhD, global medical director for hemophilia therapies at Baxter. "These two studies echo the results of our original...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-09-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry